The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substantial reduction in body size and benefit metabolic marker